U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07476170) titled 'Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China' on March 13.
Brief Summary: This study aims to fill the current gap in data regarding HR+/HER2- ABC 1L treatment patterns and outcomes in the real-world setting in China, especially in the context of the widespread application of CDK4/6is and the lack of sufficient evidence for ribociclib as a most recently marketed drug in the real-world setting.
Study Start Date: March 25
Study Type: OBSERVATIONAL
Condition:
HR+/HER2- Advanced or Metastatic Breast Cancer
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Ph...